In patients with type 2 diabetes, GLP-1 receptor agonists have been associated with lower incidence rates of stroke onset, cardiovascular events, and mortality linked to heart-related conditions (Malhotra et al., 2020). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.